RecruitingPhase 2Phase 3NCT06796803

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Camrelizumab and Rivoceranib Plus HAIC as Conversion Therapy for Potentially Resectable Intermediate-advanced Hepatocellular Carcinoma: a Multicenter, Open-label, Randomized, Phase 2/3 Study

Sponsor

Shanghai Zhongshan Hospital

Enrollment

398 participants

Start Date

Feb 20, 2025

Study Type

INTERVENTIONAL

Conditions

Potentially Resectable Hepatocellular Carcinoma

Summary

The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called camerlizumab + rivoceranib and a drug called camrelizumab combined with rivoceranib and HAIC for people with potentially resectable hepatocellular carcinoma. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGcamrelizumab combined with rivoceranib and HAIC

systemic therapy combined with locoregional theraphy as conversion therapy

DRUGcamerlizumab + rivoceranib

systemic therapy

Locations(2)

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Zhongshan Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06796803